Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026)
Acumen Pharmaceuticals' Common Equity came in at $57.26 million for Q2 2026, down 51.1% from $117.08 million a year earlier and down 34.5% from the prior quarter.
Powered by 
Analysis
Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Acumen Pharmaceuticals' Common Equity was $70.43 million, down 61.3% from FY2024.
- Going back by year, Common Equity was $181.82 million in FY2024 (-31.9%), $266.97 million in FY2023 (+41.4%), $188.78 million in FY2022 (-16.2%) and $225.18 million in FY2021.
- The Q2 2026 figure represents the lowest quarterly Common Equity since Q2 2021.
- Year-over-year, Common Equity has declined for eight consecutive quarters, with an average decline of 45.0% over the last eight quarters.
- The fastest year-over-year change in Common Equity over five years came in Q1 2024 (growth of 46.3%), and the weakest in Q4 2025 (a decline of 61.3%).
- Business Quant data shows ABOS's Common Equity at $87.48 million (Q1 2026), $70.43 million (Q4 2025) and $93.17 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,133.15 Bn | 1,101.73 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 616.41 Bn | 534.94 Bn | 17.26 Bn | 84.97 Bn |
| 3 | AbbVie | 501.01 Bn | 474.12 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 367.15 Bn | 321.53 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 298.00 Bn | 261.99 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 261.56 Bn | 235.25 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 235.40 Bn | 190.80 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 190.38 Bn | 164.57 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 169.76 Bn | 116.40 Bn | 10.94 Bn | 85.49 Bn |
| 10 | Acumen Pharmaceuticals | 148.84 Mn | -333.23 Mn | - | 57.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57.26 Mn |
| Mar 31, 2026 | 87.48 Mn |
| Dec 31, 2025 | 70.43 Mn |
| Sep 30, 2025 | 93.17 Mn |
| Jun 30, 2025 | 117.08 Mn |
| Mar 31, 2025 | 155.52 Mn |
| Dec 31, 2024 | 181.82 Mn |
| Sep 30, 2024 | 217.20 Mn |
| Jun 30, 2024 | 243.95 Mn |
| Mar 31, 2024 | 262.03 Mn |
| Dec 31, 2023 | 266.97 Mn |
| Sep 30, 2023 | 280.27 Mn |
| Jun 30, 2023 | 168.87 Mn |
| Mar 31, 2023 | 179.09 Mn |
| Dec 31, 2022 | 188.78 Mn |
| Sep 30, 2022 | 196.65 Mn |
| Jun 30, 2022 | 206.52 Mn |
| Mar 31, 2022 | 216.09 Mn |
| Dec 31, 2021 | 225.18 Mn |
| Sep 30, 2021 | 233.36 Mn |
API Access
Acumen Pharmaceuticals Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ABOS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ABOS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ABOS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();